A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

Peggy Wu, Youn H. Kim, Phillip W. Lavori, Richard T. Hoppe, Keith E. Stockerl-Goldstein

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The survival outlook in advanced mycosis fungoides (MF) is poor. Autologous and allogeneic stem cell transplants (SCT) have been shown, in small case series and case reports, to have the potential for long-term remission or to alter disease course. Allogeneic SCT is thought to have a curative potential secondary to a graft-versus-lymphoma (GVL) effect. A patient-level meta-analysis was performed to compare the outcome of allogeneic versus autologous SCT in patients with MF/Sézary syndrome (SS) using 39 cases from the literature. There were a total of 20 allogeneic and 19 autologous transplant cases. The gender, age, and stage distribution was similar between the transplant groups. The allogeneic group received significantly more systemic therapies prior to transplant (P < .0005) and had longer follow-up after transplant. Overall survival (OS) results showed a more favorable outcome of patients who received allogeneic SCT (P = .027). Event-free survival (EFS) demonstrated a more durable response in patients who received allogeneic SCT (P = .002). In the allogeneic group, the majority (70%) of patients experienced persistent graft-versus-host disease (GVHD), mostly with mild to moderate severity, and 2 of 4 deaths were related to GVHD. Meanwhile, the majority of the deaths (8 of 10) in the autologous group were because of progressive disease. These results support the belief that allogeneic SCT offers a better survival and disease-free outcome versus autologous SCT in MF/SS, likely because of a GVL effect.

Original languageEnglish (US)
Pages (from-to)982-990
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number8
DOIs
StatePublished - Aug 1 2009
Externally publishedYes

Fingerprint

Mycosis Fungoides
Hematopoietic Stem Cells
Meta-Analysis
Transplants
Stem Cells
Graft vs Host Disease
Disease-Free Survival
Lymphoma
Survival
Age Distribution
Autografts

Keywords

  • Allogeneic stem cell transplant
  • Autologous stem cell transplant
  • Cutaneous T cell lymphoma
  • Mycosis fungoides
  • Sézary Syndrome

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome. / Wu, Peggy; Kim, Youn H.; Lavori, Phillip W.; Hoppe, Richard T.; Stockerl-Goldstein, Keith E.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 8, 01.08.2009, p. 982-990.

Research output: Contribution to journalArticle

Wu, Peggy ; Kim, Youn H. ; Lavori, Phillip W. ; Hoppe, Richard T. ; Stockerl-Goldstein, Keith E. / A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 8. pp. 982-990.
@article{f043d97911764663a9c2815aabd00452,
title = "A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and S{\'e}zary Syndrome",
abstract = "The survival outlook in advanced mycosis fungoides (MF) is poor. Autologous and allogeneic stem cell transplants (SCT) have been shown, in small case series and case reports, to have the potential for long-term remission or to alter disease course. Allogeneic SCT is thought to have a curative potential secondary to a graft-versus-lymphoma (GVL) effect. A patient-level meta-analysis was performed to compare the outcome of allogeneic versus autologous SCT in patients with MF/S{\'e}zary syndrome (SS) using 39 cases from the literature. There were a total of 20 allogeneic and 19 autologous transplant cases. The gender, age, and stage distribution was similar between the transplant groups. The allogeneic group received significantly more systemic therapies prior to transplant (P < .0005) and had longer follow-up after transplant. Overall survival (OS) results showed a more favorable outcome of patients who received allogeneic SCT (P = .027). Event-free survival (EFS) demonstrated a more durable response in patients who received allogeneic SCT (P = .002). In the allogeneic group, the majority (70{\%}) of patients experienced persistent graft-versus-host disease (GVHD), mostly with mild to moderate severity, and 2 of 4 deaths were related to GVHD. Meanwhile, the majority of the deaths (8 of 10) in the autologous group were because of progressive disease. These results support the belief that allogeneic SCT offers a better survival and disease-free outcome versus autologous SCT in MF/SS, likely because of a GVL effect.",
keywords = "Allogeneic stem cell transplant, Autologous stem cell transplant, Cutaneous T cell lymphoma, Mycosis fungoides, S{\'e}zary Syndrome",
author = "Peggy Wu and Kim, {Youn H.} and Lavori, {Phillip W.} and Hoppe, {Richard T.} and Stockerl-Goldstein, {Keith E.}",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.bbmt.2009.04.017",
language = "English (US)",
volume = "15",
pages = "982--990",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

AU - Wu, Peggy

AU - Kim, Youn H.

AU - Lavori, Phillip W.

AU - Hoppe, Richard T.

AU - Stockerl-Goldstein, Keith E.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - The survival outlook in advanced mycosis fungoides (MF) is poor. Autologous and allogeneic stem cell transplants (SCT) have been shown, in small case series and case reports, to have the potential for long-term remission or to alter disease course. Allogeneic SCT is thought to have a curative potential secondary to a graft-versus-lymphoma (GVL) effect. A patient-level meta-analysis was performed to compare the outcome of allogeneic versus autologous SCT in patients with MF/Sézary syndrome (SS) using 39 cases from the literature. There were a total of 20 allogeneic and 19 autologous transplant cases. The gender, age, and stage distribution was similar between the transplant groups. The allogeneic group received significantly more systemic therapies prior to transplant (P < .0005) and had longer follow-up after transplant. Overall survival (OS) results showed a more favorable outcome of patients who received allogeneic SCT (P = .027). Event-free survival (EFS) demonstrated a more durable response in patients who received allogeneic SCT (P = .002). In the allogeneic group, the majority (70%) of patients experienced persistent graft-versus-host disease (GVHD), mostly with mild to moderate severity, and 2 of 4 deaths were related to GVHD. Meanwhile, the majority of the deaths (8 of 10) in the autologous group were because of progressive disease. These results support the belief that allogeneic SCT offers a better survival and disease-free outcome versus autologous SCT in MF/SS, likely because of a GVL effect.

AB - The survival outlook in advanced mycosis fungoides (MF) is poor. Autologous and allogeneic stem cell transplants (SCT) have been shown, in small case series and case reports, to have the potential for long-term remission or to alter disease course. Allogeneic SCT is thought to have a curative potential secondary to a graft-versus-lymphoma (GVL) effect. A patient-level meta-analysis was performed to compare the outcome of allogeneic versus autologous SCT in patients with MF/Sézary syndrome (SS) using 39 cases from the literature. There were a total of 20 allogeneic and 19 autologous transplant cases. The gender, age, and stage distribution was similar between the transplant groups. The allogeneic group received significantly more systemic therapies prior to transplant (P < .0005) and had longer follow-up after transplant. Overall survival (OS) results showed a more favorable outcome of patients who received allogeneic SCT (P = .027). Event-free survival (EFS) demonstrated a more durable response in patients who received allogeneic SCT (P = .002). In the allogeneic group, the majority (70%) of patients experienced persistent graft-versus-host disease (GVHD), mostly with mild to moderate severity, and 2 of 4 deaths were related to GVHD. Meanwhile, the majority of the deaths (8 of 10) in the autologous group were because of progressive disease. These results support the belief that allogeneic SCT offers a better survival and disease-free outcome versus autologous SCT in MF/SS, likely because of a GVL effect.

KW - Allogeneic stem cell transplant

KW - Autologous stem cell transplant

KW - Cutaneous T cell lymphoma

KW - Mycosis fungoides

KW - Sézary Syndrome

UR - http://www.scopus.com/inward/record.url?scp=67649583532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649583532&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.04.017

DO - 10.1016/j.bbmt.2009.04.017

M3 - Article

C2 - 19589488

AN - SCOPUS:67649583532

VL - 15

SP - 982

EP - 990

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -